Boom Capital Ventures

Olio Labs utilizes AI for combo therapeutics, optimizing and minimizing side effects through automated discovery of protein interactions.

Bioptimus specializes in the development of a universal artificial intelligence foundation model aimed at enhancing scientific research and biotechnological innovation. The company's technology seamlessly connects various scales of biology, ranging from molecules to cells, tissues, and entire organisms. By transforming multiscale data into actionable representations, Bioptimus enables its clients to drive breakthrough discoveries and accelerate advancements in the biomedical field.

Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.

BioLoomics, Inc. is a biotechnology company based in Boulder, Colorado, founded in 2019. It specializes in drug screening services that analyze drug action and toxicity through the use of biosensors and advanced imaging technology. BioLoomics develops tools aimed at enhancing drug discovery by employing directed evolution to create antibodies with programmable spatial fate in target cells. The company's technology facilitates high-throughput multiplexed profiling of biochemical events in live mammalian cells, allowing for the screening of chemical libraries and bioactive nanoparticles. This innovative approach enables clients to observe unique cellular responses and sustainably induce hormone secretion, ultimately improving the success rates and reducing costs associated with drug development.

Sonera Magnetics is engaged in developing advanced technology for high-performance, non-invasive brain-computer interfaces, aiming to enhance access to brain diagnostics. The company has created a magnetometer capable of measuring weak magnetic fields produced by brain activity, utilizing acoustically-driven ferromagnetic resonance. This technology operates at room temperature and in compact, portable formats, achieving sensitivity comparable to leading diagnostic tools that use superconducting sensors. Sonera Magnetics' systems are designed to facilitate the diagnosis and treatment of neurological disorders, such as epilepsy and dementia, by providing reliable brain imaging capabilities. Founded in 2018 in Berkeley, California, by Nishita Deka, Dominic Labanowski, and Sayeef Salahuddin, the company seeks to offer a practical and cost-effective solution for brain-computer interfacing.

Harmonic Discovery is a pharmaceutical company focused on developing a platform that addresses cancer resistance mechanisms through innovative drug design. The company's platform integrates biological screening, medicinal chemistry, and computational chemistry, employing structural modeling and machine learning to predict potential clinical resistance mutations. This approach allows for the optimization of small molecule therapeutics, ensuring they effectively target cancer while minimizing undesirable off-target interactions. By combining computation with experimental data, Harmonic Discovery aims to enhance treatment outcomes for cancer patients.

Monod Bio is a life sciences company based in Seattle, Washington, focused on developing innovative biosensors for detecting proteins, toxins, antibodies, and other analytes. Founded in 2021, the company has created a biosensor platform that integrates binding, transduction, and amplification processes in a single step, allowing for the rapid and sensitive detection of a diverse array of target molecules. By leveraging recent advancements in computational protein engineering, Monod Bio has designed highly modular bio-sensing nanoswitches that facilitate cost-effective analytical assays. This technology aims to enhance the capabilities of the healthcare industry in biotechnology and medicine.

Endpoint Health, Inc. is a precision immunology company based in Palo Alto, California, with additional offices in Michigan and Illinois. Founded in 2018, the company focuses on researching and developing therapies that integrate therapeutics, companion diagnostics, and artificial intelligence. Its mission is to enhance patient outcomes, particularly for individuals suffering from critical illnesses such as sepsis, acute respiratory distress syndrome, and COVID-19. By utilizing its proprietary AI-powered platform, OMNAI, Endpoint Health aims to identify and match effective therapies with patients who are most likely to benefit from them, moving beyond traditional one-size-fits-all approaches in drug development. Through this strategy, the company seeks to deliver personalized treatments that can significantly improve the health outcomes of patients with autoimmune and inflammatory conditions.

Synthesis AI, Inc. is a data generation platform based in San Francisco, California, that specializes in synthetic data technology for computer vision applications. Founded in 2019, the company aims to enhance the capabilities of artificial intelligence by providing a solution that allows leading computer vision teams to create more effective models in a faster and more cost-efficient manner. Synthesis AI integrates innovative generative artificial intelligence models with cinematic visual effects to produce photorealistic and diverse images and videos, complete with accurate pixel-level labels. This technology enables clients to generate simulated and synthetic data, particularly for automotive applications, thereby accelerating the development of advanced AI systems.

Diligent Robotics Inc. is a company based in Austin, Texas, that develops and manufactures hospital service robots, specifically designed to assist clinical and nursing staff with logistical tasks. Its flagship product, Moxi, is a robotic assistant equipped with advanced mobile manipulation, social intelligence, and human-guided learning capabilities. Moxi works collaboratively with healthcare teams, allowing clinical staff to focus more on direct patient care, thereby enhancing patient satisfaction and improving the overall quality and safety of service. Founded in 2017, Diligent Robotics aims to integrate artificial intelligence technologies into everyday environments, supporting healthcare providers in dynamic and semi-structured settings.

Fauna Bio Incorporated is a biotechnology company based in San Francisco, California, founded in 2018. It specializes in developing a cross-mammal drug discovery platform aimed at treating human diseases, including heart disease and neurodegenerative disorders. By studying the mechanisms that allow certain animals, such as hibernating and deep-diving species, to withstand extreme conditions, Fauna Bio seeks to uncover insights that can enhance human health. The company utilizes animal genomics, transcriptomics, metabolomics, and proteomics data from a diverse range of species to identify novel drug targets and facilitate pre-clinical and early clinical testing of new therapeutics. Through its innovative approach, Fauna Bio aims to improve recovery from serious medical events like trauma, heart attacks, and strokes.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

Shiok Meats is a Singapore-based company founded in 2018 that specializes in cellular aquaculture, focusing on the production of cell-based meats and seafood. By harvesting from cells rather than animals, the company aims to provide clean and healthy alternatives to traditional meat products. Its primary offerings include lab-cultured shrimp and other crustacean meats, which are designed to be animal-friendly, health-conscious, and environmentally sustainable. Shiok Meats strives to deliver products that retain the same taste, texture, and nutritional value as conventional seafood, thereby catering to consumers seeking healthier and more ethical food options.

Orchid is a reproductive technology startup founded in 2019 and headquartered in San Francisco, California. The company specializes in detecting rare genetic disorders through its preconception system, which analyzes the genomes of both partners to assess genetic predispositions to various diseases, including heart disease, Alzheimer’s, and certain types of cancer. Orchid provides a “Couple Report” that incorporates results from an at-home saliva test, allowing couples to understand the potential genetic risks for their future children. If elevated risks are identified, Orchid offers valuable insights to guide couples in monitoring health markers, adjusting their diets, or considering procedures such as in vitro fertilization. The company collaborates with experts in reproductive medicine and genetics to ensure the accuracy of its results.

Synthesis AI, Inc. is a data generation platform based in San Francisco, California, that specializes in synthetic data technology for computer vision applications. Founded in 2019, the company aims to enhance the capabilities of artificial intelligence by providing a solution that allows leading computer vision teams to create more effective models in a faster and more cost-efficient manner. Synthesis AI integrates innovative generative artificial intelligence models with cinematic visual effects to produce photorealistic and diverse images and videos, complete with accurate pixel-level labels. This technology enables clients to generate simulated and synthetic data, particularly for automotive applications, thereby accelerating the development of advanced AI systems.

Membio's single-use 0.2-10 L benchtop bioreactor system uses a proprietary design to provide a constant environment for cells at all scales. One technique will provide the same outcomes at all scales, whether at 0.2 L, 10 L, or anywhere in between. Fully automated single-use bioreactors designed by the business to enable cost-effective and scalable manufacture.

Diligent Robotics Inc. is a company based in Austin, Texas, that develops and manufactures hospital service robots, specifically designed to assist clinical and nursing staff with logistical tasks. Its flagship product, Moxi, is a robotic assistant equipped with advanced mobile manipulation, social intelligence, and human-guided learning capabilities. Moxi works collaboratively with healthcare teams, allowing clinical staff to focus more on direct patient care, thereby enhancing patient satisfaction and improving the overall quality and safety of service. Founded in 2017, Diligent Robotics aims to integrate artificial intelligence technologies into everyday environments, supporting healthcare providers in dynamic and semi-structured settings.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Shiok Meats is a Singapore-based company founded in 2018 that specializes in cellular aquaculture, focusing on the production of cell-based meats and seafood. By harvesting from cells rather than animals, the company aims to provide clean and healthy alternatives to traditional meat products. Its primary offerings include lab-cultured shrimp and other crustacean meats, which are designed to be animal-friendly, health-conscious, and environmentally sustainable. Shiok Meats strives to deliver products that retain the same taste, texture, and nutritional value as conventional seafood, thereby catering to consumers seeking healthier and more ethical food options.

Fauna Bio Incorporated is a biotechnology company based in San Francisco, California, founded in 2018. It specializes in developing a cross-mammal drug discovery platform aimed at treating human diseases, including heart disease and neurodegenerative disorders. By studying the mechanisms that allow certain animals, such as hibernating and deep-diving species, to withstand extreme conditions, Fauna Bio seeks to uncover insights that can enhance human health. The company utilizes animal genomics, transcriptomics, metabolomics, and proteomics data from a diverse range of species to identify novel drug targets and facilitate pre-clinical and early clinical testing of new therapeutics. Through its innovative approach, Fauna Bio aims to improve recovery from serious medical events like trauma, heart attacks, and strokes.

Shiok Meats is a Singapore-based company founded in 2018 that specializes in cellular aquaculture, focusing on the production of cell-based meats and seafood. By harvesting from cells rather than animals, the company aims to provide clean and healthy alternatives to traditional meat products. Its primary offerings include lab-cultured shrimp and other crustacean meats, which are designed to be animal-friendly, health-conscious, and environmentally sustainable. Shiok Meats strives to deliver products that retain the same taste, texture, and nutritional value as conventional seafood, thereby catering to consumers seeking healthier and more ethical food options.

Diligent Robotics Inc. is a company based in Austin, Texas, that develops and manufactures hospital service robots, specifically designed to assist clinical and nursing staff with logistical tasks. Its flagship product, Moxi, is a robotic assistant equipped with advanced mobile manipulation, social intelligence, and human-guided learning capabilities. Moxi works collaboratively with healthcare teams, allowing clinical staff to focus more on direct patient care, thereby enhancing patient satisfaction and improving the overall quality and safety of service. Founded in 2017, Diligent Robotics aims to integrate artificial intelligence technologies into everyday environments, supporting healthcare providers in dynamic and semi-structured settings.